Back to drug list

Elaprase (idursulfase)


Billing

Code: J1743

Description: Idursulfase injection

Unit: 1 mg

Payment: $542.918

Pay quarter: Q3 2023


Medicare history

Dosage and Frequency

Hunter syndrome (Mucopolysaccharidosis II, MPS II)

• 0.5mg/kg IV every 1 week

Calculate drug reimbursement


Total Reimbursement:

$23,019.72

(ASP: $21,716.72, Margin: $1,303.00)


Code:

J1743

# Units to bill:

40

Prior Authorization

Prior auth criteria for Elaprase may include but is not limited to:


1. The patient must be 6 years of age or older.
2. The patient must have been diagnosed with Hunter syndrome (mucopolysaccharidosis II).
3. The patient must have experienced a decline in physical, cognitive, or behavioral function as measured by at least one of the following assessments: Bayley Scales of Infant Development-III (BSID-III), Vineland Adaptive Behavior Scales (VABS), or Psychoeducational Profile-Revised (PEP-R).
4. The patient must have had a total lysosomal enzyme activity level test and the results must have revealed an activity level of ?2% of normal.
5. The patient must not have received Elaprase in the past.
6. The patient must not have any known hypersensitivity to the active ingredient, iduronate-2-sulfatase.
7. The patient must not be pregnant or breastfeeding.
8. The patient must not have any other medical condition that may increase the risk of adverse reactions from Elaprase.


Insurance prior auth guidelines:

Aetna

United Healthcare

Anthem

Cigna


Billable NDCs

54092-0700-01

ELAPRASE (TAKEDA PHARMACEUTICALS AMERICA, INC.)

6 MG



Resources

Website